June 20, 2017 10:38 AM EDT
Editor's note

Cheers! End­points News turns 1 to­day — and we're un­wrap­ping in­fo on a new sub­scrip­tion plan

John Carroll

Editor & Founder

To­day, End­points News is one year old. Like any thriv­ing in­fant, we’ve been grow­ing at a fast pace, out­grow­ing a hasti­ly craft­ed chris­ten­ing gar­ment. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Eli Lil­ly re­ports first Phase 3 da­ta for oral GLP-1, post­ing a win in di­a­betes

Sarep­ta los­es CMO to RNA edit­ing up­start; An­oth­er wave of per­son­nel moves at Dyne

Nether­lands pours $1.5B in­to biotech in pur­suit of glob­al lead­er­ship am­bi­tions

Sanofi to pay $125M up­front for two im­munol­o­gy drugs from lit­tle-known biotech

Ex­clu­sive: BigHat inks Lil­ly deal for AI-boost­ed an­ti­bod­ies, ex­tends Se­ries B

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times